Integrated Bioscience Section, Graduate School of Science and Technology, National University Corporation, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Integrated Bioscience Section, Graduate School of Science and Technology, National University Corporation, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.
Biochem Biophys Res Commun. 2022 Feb 12;592:1-6. doi: 10.1016/j.bbrc.2022.01.002. Epub 2022 Jan 5.
Currently, semiconductor nanoparticles known as quantum dots (QDs) have attracted interest in various application fields such as those requiring sensing properties, binding assays, and cellular imaging and are the very important in the acceleration of drug discovery due to their unique photophysical properties. Here, we applied graphene quantum dots (GQDs) for the binding assay of membrane progesterone receptor alpha (mPRα), one of the probable membrane receptors that have potential in drug discovery applications. By coupling the amino groups of mPRα with GQDs, we prepared fluorogenic GQD-conjugated mPRα (GQD-mPRα). When mixed with a progesterone-BSA-fluorescein isothiocyanate conjugate (P4-BSA-FITC) to check the ligand receptor binding activity of GQD-mPRα, fluorescence at 520 nm appeared. The fluorescence at 520 nm was reduced by the addition of free progesterone into the reaction mixture. GQD-coupled BSA (GQD-BSA) did not show a reduction in fluorescence at 520 nm. The results demonstrated the formation of a complex of GQD-mPRα and P4-BSA-FITC with ligand receptor binding. We established a ligand binding assay for membrane steroid receptors that is applicable for high-throughput assays.
目前,半导体纳米粒子(量子点)因其独特的光物理特性,在需要传感性能、结合测定、细胞成像等各种应用领域引起了人们的兴趣,是加速药物发现的重要工具。在这里,我们将石墨烯量子点(GQDs)应用于膜孕激素受体α(mPRα)的结合测定,mPRα 是药物发现应用中具有潜力的可能膜受体之一。通过将 mPRα 的氨基与 GQDs 偶联,我们制备了荧光 GQD 偶联 mPRα(GQD-mPRα)。当与孕激素-BSA-异硫氰酸荧光素缀合物(P4-BSA-FITC)混合以检查 GQD-mPRα 的配体受体结合活性时,在 520nm 处出现荧光。当向反应混合物中加入游离孕激素时,在 520nm 处的荧光减少。GQD 偶联的 BSA(GQD-BSA)在 520nm 处没有荧光减少。结果表明,GQD-mPRα 与 P4-BSA-FITC 形成了具有配体受体结合的复合物。我们建立了一种适用于高通量测定的膜甾体受体配体结合测定法。